Clinical Trial

BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma

Name: BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma — clinical trial record (NCT07008053)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a multi-center, prospective study. The main purpose is to evaluate the efficacy and safety of BR (bendamustine and zuberitamab) combined with OR (orelabrutinib and zuberitamab) in treatment-naïve patients with marginal zone lymphoma.

Trial Details

NCT Number	NCT07008053
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Marginal Zone Lymphomas
Enrollment	37 participants
Start Date	2025-07
Primary Completion	2027-07 (estimated)
Study Completion	2028-11 (estimated)
Updated on ClinicalTrials.gov	2025-06-06